• admin@condrug.com
  • Mon - Sat: 8.00 am - 7.00 pm

We develop solutions for your clinical data needs

Linkedin-in Link
ConDrug
  • Workspace
  • ConDrug Pharmacovigilance
  • Blog
  • About Us
  • Contacts

Have Any Questions?

+1 (877) 703-6664

Platform
ConDrug
  • Workspace
  • ConDrug Pharmacovigilance
  • Blog
  • About Us
  • Contacts

Blog

New Drugs

Gefapixant for Chronic Cough: How This P2X3 Antagonist Is Changing Treatment

Learn how gefapixant, a first-in-class P2X3 receptor antagonist, targets cough hypersensitivity to reduce chronic refractory cough, improve quality of life, and offer an alternative to off‑label neuromodulators.

New Drugs

What Is Retatrutide? Triple Agonist Weight Loss Drug Explained (GLP‑1, GIP, Glucagon)

Learn what retatrutide is, how this next‑generation triple agonist (GLP‑1, GIP, and glucagon) works for weight loss, obesity, and metabolic health, and see key phase 2 clinical trial results on body‑weight reduction and cardiometabolic benefits.

New Drugs

Ensifentrine for COPD: Dual PDE3/4 Inhibitor Mechanism, Benefits & Clinical Data

Learn what ensifentrine is, how its dual PDE3/4 inhibition works, and why it’s an emerging inhaled treatment option for COPD. Review its bronchodilatory and anti-inflammatory effects, phase 2b and phase 3 clinical trial results, and impact on lung function, symptoms, and exacerbations.

New Drugs

Zuranolone for Depression: How This New GABAA Modulator Differs From Traditional Antidepressants

Discover how zuranolone (SAGE-217), a first-in-class oral neuroactive steroid, offers rapid relief for major depressive disorder and postpartum depression through short 14-day treatment cycles and a novel GABAA receptor mechanism, reshaping options for treatment-resistant depression.

Pharmacovigilance

AI-Driven Pharmacovigilance: How Intelligent Safety Systems Transform Drug Risk Management

Discover how AI-driven pharmacovigilance is transforming drug safety with intelligent systems that automate case processing, enhance signal detection, and enable proactive risk management across real-world data sources.

New Drugs

Marituglutide vs Semaglutide: Dual Incretin Agonist for Weight Loss & Diabetes

Learn what marituglutide is, how its dual GLP-1/GIP “twincretin” mechanism works, and how it may outperform semaglutide for weight loss, glycemic control, and metabolic health in obesity and type 2 diabetes.

Pharmacovigilance

AI in Pharmacovigilance: Transforming Drug Safety Monitoring and Signal Detection

Discover how AI and machine learning are revolutionizing pharmacovigilance by enabling real-time signal detection, mining unstructured data from EHRs and social media, and improving drug safety monitoring across the product life cycle.

Protein-Peptide Drugs

Tirzepatide: Dual GIP/GLP‑1 “Twincretin” Redefining Peptide Therapies for Type 2 Diabetes and Obesity

Discover how tirzepatide, a once-weekly dual GIP/GLP‑1 “twincretin,” is transforming type 2 diabetes and obesity treatment through engineered peptide design, extended half‑life, and superior HbA1c and weight reduction compared with traditional GLP‑1 agonists.

New Drugs

Zuranolone: Fast-Acting Oral Antidepressant for MDD and Postpartum Depression

Learn what zuranolone is, how this first-in-class oral neuroactive steroid works on GABA-A receptors, and why it’s generating buzz as a rapid-acting treatment option for major depressive disorder (MDD) and postpartum depression (PPD).

Pharmacovigilance

Intelligent Signal Detection in Pharmacovigilance: How AI Is Transforming Drug Safety

Discover how AI-powered intelligent signal detection is reshaping pharmacovigilance. Learn how NLP and machine learning enhance drug safety, improve signal prioritization, and help meet regulatory expectations in modern pharmacovigilance.

  • 1
  • 2
  • 3
  • 4
  • …
  • 20
  • 21
  • 22
Categories
  • New Drugs (53)
  • Pharmacovigilance (73)
  • Protein-Peptide Drugs (41)
  • Small Molecule Drugs (45)
Tags
adverse drug reactions adverse event detection AI in drug safety AI in Healthcare AI in Pharmacovigilance artificial intelligence deucravacitinib drug discovery Drug Safety GIP GIP GLP-1 dual agonist GLP-1 GLP-1 agonist healthcare AI healthcare data incretin therapy Life Sciences Machine Learning machine learning in healthcare machine learning in pharma] metabolic disease metabolic health migraine treatment NLP obesity treatment peptide therapeutics pharmacovigilance pharmacovigilance automation PROTACs real-world data] real-world evidence signal detection small molecule design small molecule drugs SURPASS trials targeted protein degradation tirzepatide TYK2 inhibitor type 2 diabetes type 2 diabetes treatment weight loss weight loss drugs weight loss medication [AI drug discovery [AI pharmacovigilance
Recent Posts
  • Gefapixant for Chronic Cough: How This P2X3 Antagonist Is Changing Treatment
    17/12/2025
  • What Is Retatrutide? Triple Agonist Weight Loss Drug Explained (GLP‑1, GIP, Glucagon)
    17/12/2025
  • Ensifentrine for COPD: Dual PDE3/4 Inhibitor Mechanism, Benefits & Clinical Data
    17/12/2025

411 University St, Seattle, USA

Our Address

admin@condrug.com

Our Mailbox

+1 (877) 703-6664

Our Phone
  • Home
  • Workspace
  • Contacts

Copyright © 2025 ConDrug All Rights Reserved.

Linkedin-in Handshake